共查询到20条相似文献,搜索用时 15 毫秒
1.
V M Dixit D M Haverstick K M O''Rourke S W Hennessy G A Grant S A Santoro W A Frazier 《Proceedings of the National Academy of Sciences of the United States of America》1985,82(10):3472-3476
A monoclonal antibody (C6.7) has been generated against the calcium-replete form of human platelet thrombospondin (TSP). C6.7 is specific for TSP as determined by both competitive radioimmunoassay and immunoprecipitation. This antibody inhibits both thrombin- and A23187-induced aggregation of gel-filtered platelets in a concentration-dependent manner without affecting the secretion of serotonin. The epitope on TSP recognized by C6.7 has been localized to an 18-kDa fragment that is present in mild chymotryptic digests of TSP. This fragment is disulfide-linked to a 120- to 140-kDa fragment in unreduced digests, and both reduction and denaturation are required to separate the 18-kDa peptide from the larger fragments. A 25-kDa heparin binding domain is also present in the chymotryptic digest. However, the 18-kDa peptide is distinct from the heparin binding domain. The amino acid sequence at the NH2 terminus of the 18-kDa fragment is Asp-Thr-Asn-Pro-Thr-Arg-Ala-Gln-Gly-Tyr-. 相似文献
2.
C L Balduini F Sinigallia G Damiani G Bertolino A Bisio E Zocchi 《Experimental hematology》1986,14(5):338-342
A murine monoclonal antibody against glycoproteins IIb-IIIa of platelet membrane completely abolished platelet aggregation induced by epinephrine, arachidonic acid, and low concentration of collagen and thrombin, but it had only minor inhibitory effects on aggregation induced by ADP, higher amounts of collagen and thrombin, and these agents combined in pairs. The simultaneous studies of aggregation and ATP secretion demonstrated that aggregation plays an essential role in stimulating the platelet-release reaction, except for the thrombin-induced ATP secretion that seems to be largely dependent on fibrinogen binding to platelet surface. 相似文献
3.
Inhibition of fibrinogen binding to stimulated human platelets by a monoclonal antibody. 总被引:30,自引:7,他引:30
下载免费PDF全文
![点击此处可从《Proceedings of the National Academy of Sciences of the United States of America》网站下载免费的PDF全文](/ch/ext_images/free.gif)
J S Bennett J A Hoxie S F Leitman G Vilaire D B Cines 《Proceedings of the National Academy of Sciences of the United States of America》1983,80(9):2417-2421
Fibrinogen binding to receptors on stimulated platelets is a prerequisite for platelet aggregation. To gain further insight into the role of fibrinogen in platelet aggregation and to identify the platelet fibrinogen receptor, we developed a monoclonal anti-platelet antibody that inhibited platelet aggregation. The purified antibody, designated A2A9, inhibited platelet aggregation stimulated by 10 microM ADP, 10 microM epinephrine, and thrombin at 1 unit/ml without inhibiting platelet shape change or platelet secretion. A2A9 was also a competitive inhibitor of fibrinogen binding to ADP-stimulated platelets. Fifty percent inhibition of fibrinogen binding occurred at 65 nM A2A9. Direct binding studies using radiolabeled A2A9 demonstrated 47,000 A2A9 binding sites on unstimulated platelets, with a dissociation constant of 60 nM. Platelets from two individuals with Glanzmann thrombasthenia bound essentially no A2A9. Therefore, these data support the hypothesis that receptor-bound fibrinogen mediates platelet aggregation. In order to identify the platelet fibrinogen receptor, A2A9 immobilized on agarose was used for affinity chromatography. Two platelet polypeptides with Mr = 140,000 and 93,000 were recovered from the immobilized A2A9. After disulfide reduction, these Mr values were altered to 125,000 and 116,000. The smaller polypeptide was also found to contain the PlA1 antigen. These data localize the epitope recognized by A2A9 to the platelet membrane glycoprotein IIb-IIIa complex and suggest that this complex forms the physiologic platelet fibrinogen receptor. 相似文献
4.
5.
The monoclonal antibody (MAb) GAP 5.9 directed against platelet glycoprotein IIb is described. This MAb is able to induce aggregation of platelet rich plasma in the absence of further stimuli and likely recognizes a glycoprotein epitope not closely related to calcium binding sites on the molecule. 相似文献
6.
Inhibition of platelet aggregation by protease inhibitors. Possible involvement of proteases in platelet aggregation 总被引:4,自引:0,他引:4
The possible participation of proteases in human platelet aggregation was explored using various protease inhibitors and substrates. Protease inhibitors used included naturally occurring inhibitors of serine proteases and synthetic inhibitors that modify the active site of protease. Substrates used were synthetic substrates for the trypsin type as well as for the chymotrypsin type of protease. All these inhibitors and substrates inhibited platelet aggregation and serotonin release induced by ADP, collagen, epinephrine, or thrombin. In ADP- and epinephrine-induced platelet aggregation the second phase of aggregation was most efficiently inhibited. The inhibitors suppressed the formation of malondialdehyde during platelet aggregation. Release by aggregating agents of arachidonate and its metabolites from indomethacin-treated platelets as well as nontreated platelets was also inhibited. The inhibitors apperar to interact with stimulated platelets but not with unstimulated platelets. These observations suggest that the interaction of an aggregating agent with its platelet receptor activates a unique precursor serine protease that in turn activates platelet phospholipase to liberate arachidonic acid (the precursor of the potent platelet aggregating agent thromboxane A2) from platelet phospholipids. 相似文献
7.
《Platelets》2013,24(1-2):59-67
A new murine monoclonal antibody, MDP-1, specific for human platelet glycoprotein IIIa has been produced and characterized. Following SDS-polyacrylamide gel electrophoresis, MDP-1 reacted with a 94kDa protein immobilized on a nitrocellulose membrane. Upon reduction, MDP-1 no longer bound to the 94kDa protein indicating an epitope requiring at least one disulfide bond. On crossed immunoelectrophoresis MDP-1 reacted to the same peak as the GP IIb-IIIa complex-specific antibody AP-2. After dissociation of the GP IIb-IIIa complex with EDTA, AP-2 showed no reactivity while MDP-1 bound to a new peak that was broader and anodal to the original GP IIb-IIIa peak, consistent with GP IIIa. MDP-1 inhibited ADP and thrombin induced aggregation. In addition, MDP-1 inhibited ADP induced release of ATP, but did not inhibit thrombin stimulated ATP release. Following chymotrypsin digestion, MDP-1 bound to a cleaved GP IIIa protein (nonreduced M, = 122 kDa) consistent with opening of the major disulfide loop. A second cleavage resulted in a 63 kDa species that reacted with MDP-1. Scatchard analysis revealed 22 000 molecules of MDP-1 bound per platelet, and indicated a type of binding consistent with positive cooperativity. The antibody bound equally well to stimulated and unstimulated platelets. MDP-1 binding was inhibited by a polyclonal anti-PIA1 antibody, but bound to platelets from a PIA1 negative individual indicating a binding site close to but not identical to the PIA1 epitope. In addition, MDP-1 binding was not inhibited by Arg-Gly-Asp-Ser (RGDS) suggesting that it is not directed to the RGD binding site on GP IIIa. 相似文献
8.
Kurnat AE Mattson JC Estry DW Wright S Poulik MD Chen J Davis JM Schwartz KA 《Platelets》1996,7(1-2):59-67
A new murine monoclonal antibody, MDP-1, specific for human platelet glycoprotein IIIa has been produced and characterized. Following SDS-polyacrylamide gel electrophoresis, MDP-1 reacted with a 94kDa protein immobilized on a nitrocellulose membrane. Upon reduction, MDP-1 no longer bound to the 94kDa protein indicating an epitope requiring at least one disulfide bond. On crossed immunoelectrophoresis MDP-1 reacted to the same peak as the GP IIb-IIIa complex-specific antibody AP-2. After dissociation of the GP IIb-IIIa complex with EDTA, AP-2 showed no reactivity while MDP-1 bound to a new peak that was broader and anodal to the original GP IIb-IIIa peak, consistent with GP IIIa. MDP-1 inhibited ADP and thrombin induced aggregation. In addition, MDP-1 inhibited ADP induced release of ATP, but did not inhibit thrombin stimulated ATP release. Following chymotrypsin digestion, MDP-1 bound to a cleaved GP IIIa protein (nonreduced M, = 122 kDa) consistent with opening of the major disulfide loop. A second cleavage resulted in a 63 kDa species that reacted with MDP-1. Scatchard analysis revealed 22 000 molecules of MDP-1 bound per platelet, and indicated a type of binding consistent with positive cooperativity. The antibody bound equally well to stimulated and unstimulated platelets. MDP-1 binding was inhibited by a polyclonal anti-PI(A1) antibody, but bound to platelets from a PI(A1) negative individual indicating a binding site close to but not identical to the PI(A1) epitope. In addition, MDP-1 binding was not inhibited by Arg-Gly-Asp-Ser (RGDS) suggesting that it is not directed to the RGD binding site on GP IIIa. 相似文献
9.
OBJECTIVE--To determine the optimum conditions for the demonstration of an antiplatelet effect of nitric oxide and to use these conditions to elucidate the effects of a transdermal glyceryl trinitrate patch on platelet aggregation in normal volunteers. METHODS--An open prospective crossover study. The effects of nitric oxide on platelet aggregation in whole blood and platelet rich plasma as stimulated by adenosine diphosphate and U46619 was assessed in the presence and absence of iloprost and MB22948. Optimum conditions for the demonstration of an antiplatelet effect of nitric oxide were then applied to whole blood from normal volunteers in the presence and absence of a transdermal glyceryl trinitrate patch. SETTING--University hospital. SUBJECTS--Eight normal volunteers. MAIN OUTCOME MEASURES--Platelet aggregation in the presence and absence of transdermal glyceryl trinitrate. RESULTS--The optimum conditions for the demonstration of an antiplatelet effect of nitric oxide in whole blood were collecting blood into a tube containing MB22948 and citrate and stimulating platelet aggregation with adenosine diphosphate in the presence or absence of iloprost. Using this method a significant effect of transdermal glyceryl trinitrate on platelet aggregation was shown (P < 0.03) in the presence and absence of iloprost. CONCLUSIONS--These results are consistent with an inhibitory effect on platelet aggregation of nitric oxide liberated by transdermal glyceryl trinitrate. Optimum test conditions are needed to show this effect. The clinical significance of the antiplatelet effect of transdermal glyceryl trinitrate is unknown. 相似文献
10.
López-Alemany R Longstaff C Hawley S Mirshahi M Fábregas P Jardí M Merton E Miles LA Félez J 《American journal of hematology》2003,72(4):234-242
Localization of plasmin activity on leukocyte surfaces plays a critical role in fibrinolysis as well as in pathological and physiological processes in which cells must degrade the extracellular matrix in order to migrate. The binding of plasminogen to leukocytic cell lines induces a 30- to 80-fold increase in the rate of plasminogen activation by tissue-type (tPA) and urokinase-type (uPA) plasminogen activators. In the present study we have examined the role of alpha-enolase in plasminogen activation on the cell surface. We produced and characterized a monoclonal antibody (MAb) 11G1 against purified alpha-enolase, which abrogated about 90% of cell-dependent plasminogen activation by either uPA or tPA on leukocytoid cell lines of different lineages: B-lymphocytic, T-lymphocytic, granulocytic, and monocytic cells. In addition, MAb 11G1 also blocked enhancement of plasmin formation by peripheral blood neutrophils and monocytes. In contrast, MAb 11G1 did not affect plasmin generation in the presence of fibrin, indicating that this antibody did not interact with fibrinolytic components in the absence of cells. These data suggest that, although leukocytic cells display several molecules that bind plasminogen, alpha-enolase is responsible for the majority of the promotion of plasminogen activation on the surfaces of leukocytic cells. 相似文献
11.
BACKGROUND. The comparative effects of aspirin and F(ab')2 fragments of monoclonal antibody 7E3 against the platelet glycoprotein IIb/IIIa receptor on ex vivo platelet aggregation and in vivo thrombosis were studied in a canine coronary balloon angioplasty model. METHODS AND RESULTS. Three groups were studied. Group 1 (n = 8) was pretreated with saline placebo, group 2 (n = 8) was pretreated with 325 mg aspirin, and group 3 (n = 8) was pretreated with 0.8 mg/kg 7E3 F(ab')2. Coronary angioplasty was performed in the left anterior descending coronary artery of open-chest dogs under fluoroscopic control; serial measurements of basal and hyperemic coronary blood flows were then made for 2 hours after application of an external stenosis that decreased hyperemic flow by 50%. There were no significant differences in platelet counts or hemodynamic measurements during the experiments. Platelet aggregation was decreased by treatment: group 1, 64 +/- 13% versus 50 +/- 13% (p = NS); group 2, 57 +/- 4% versus 25 +/- 4% (p less than 0.001); and group 3, 77 +/- 5% versus 10 +/- 6% (p less than 0.0002). Compared with initial measurements, the 7E3 antibody was superior to aspirin in maintaining hyperemic coronary blood flow after release of the external stenosis: group 1, 177 +/- 14 versus 21 +/- 14 ml/min (p less than 0.0003); group 2, 189 +/- 9 versus 110 +/- 28 ml/min (p less than 0.008); and group 3, 194 +/- 12 versus 181 +/- 15 ml/min (p less than 0.02). In group 1, arterial occlusion developed in five dogs, and nonocclusive thrombus was seen in three dogs. In group 2, arterial occlusion developed in one dog, and nonocclusive thrombus was seen in five dogs. No thrombotic material was visualized in group 3 dogs treated with 7E3 F(ab')2. CONCLUSIONS. In this animal model, the 7E3 antiplatelet antibody is superior to aspirin in inhibiting platelet aggregation, thrombosis, and acute closure after deep arterial injury caused by coronary balloon angioplasty. 相似文献
12.
13.
14.
The role of fibronectin in platelet aggregation 总被引:3,自引:0,他引:3
A monoclonal antibody (anti-Fn2) was prepared which was reactive with both plasma fibronectin and fibronectin located within the platelet alpha granule. Immunoblotting analysis, on thermolysin digestion fragments of fibronectin, identified two immunoreactive fragments of Mr 145 kDa and 155 kDa which are known to contain a cell and DNA binding region. Anti-Fn2 was found to inhibit binding of fibronectin to platelets and DNA. Functional platelet studies, measuring platelet aggregation and 14C-serotonin release in washed platelet systems, demonstrated the ability of anti-Fn2 to totally inhibit low dose thrombin and low-dose collagen induced platelet aggregation and serotonin release. Anti-Fn2 partially inhibited platelet aggregation induced by ADP (10 microM) and arachidonic acid, but had no effect on platelet aggregation induced by high-dose thrombin or by the calcium ionophore A23187. These studies indicate that fibronectin participates in platelet aggregation and release induced by a range of agonists and suggest that it has a more important involvement in platelet function than previously described. 相似文献
15.
Inhibition of human lymphocyte proliferation by monoclonal antibody to transferrin receptor 总被引:6,自引:2,他引:4
A monoclonal antibody, 42/6, which blocks the binding of transferrin to its receptor on the cell membrane, inhibits proliferation of human lymphocytes stimulated by phytohemagglutinin. Anti-receptor antibody B3/25, which does not block transferrin binding, does not alter the mitogenic response. Addition of soluble iron, in the form of ferric nitrilotriacetic acid, results in partial reversal of inhibition. Lymphocytes in the quiescent phase of the cell cycle at the time of 42/6 antibody addition are unable to traverse S phase, whereas cells actively proliferating when antibody is added are sensitive to its inhibitory effects throughout all phases of the cell cycle. Inhibition is static rather than cidal, since it can be reversed by removal of antibody after up to 48 hr of exposure. 相似文献
16.
Inhibition of human platelet function in vivo with a monoclonal antibody. With observations on the newly dead as experimental subjects 总被引:5,自引:0,他引:5
The F(ab')2 fragment of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor (7E3) is a potent inhibitor of both in-vitro platelet aggregation and in-vivo platelet thrombus formation in animal studies. As a first step in assessing the potential of 7E3-F(ab')2 as an antithrombotic agent for use in humans, we administered 7E3-F(ab')2 intravenously at increasing doses to a person who had just died and was being maintained on a respirator (neomort). At 0.1 and at 0.2 mg/kg body weight, 74% and 92% of the glycoprotein IIb/IIIa receptors were blocked, respectively; adenosine-diphosphate-induced platelet aggregation was inhibited by 84% and 100% at these same doses. Platelet glycoprotein Ib function remained intact, even at 0.6 mg/kg. Acute hemodynamic or hemorrhagic toxicity was not noted. This antibody fragment, a potent, immediate-acting inhibitor of platelet aggregation, may be of benefit in vaso-occlusive and thromboembolic disorders. 相似文献
17.
Defective ADP-induced aggregation was observed in in vitro streptokinases(SK)-treated normal platelet-rich plasma. Classic haemophilia and normal platelet poor plasma (PPP) treated with SK inhibit the aggregation of washed platelets; plasmin-treated normal human serum also shows an inhibitory effect on platelet aggregation. However, SK-treated von Willebrand plasmas do not inhibit the aggregation of washed platelets. This confirms the fact that the anti-aggregating effect is mainly linked to the digested factor VIII) but not to the digested fibrinogen. Defective ristocetin-induced platelet aggregation has also been observed in SK-treated plasmas. The presence of normal PPP does not modify the inhibition of the ADP-induced aggregation of washed platelets in SK-treated PPP. However, it does correct the ristocetin-induced aggregation. These results suggest that the inhibition of the ADP-induced aggregation is caused by the factor VIII degradation products, while the inhibition of the ristocetin-induced aggregation appears because of a defective von Willebrand activity of the factor VIII molecule. 相似文献
18.
Inhibition of platelet functions by a monoclonal antibody (LYP20) directed against a granule membrane glycoprotein (GMP-140/PADGEM) 总被引:3,自引:0,他引:3
Granule membrane protein (GMP-140), also known as platelet activation-dependent granule-external membrane (PAD-GEM) is an integral membrane glycoprotein that is expressed on the platelet surface following degranulation. GMP-140, also expressed by endothelial cells, is part of a new family of cell adhesion molecules (selectins) related to the endothelial leukocyte adhesion molecule (ELAM-1) and to the lymphocyte homing receptors in humans (Leu-8/TQ1) and in mouse (gp90MEL-14). The role of GMP-140 in platelet functions remains to be elucidated. In this study, a monoclonal antibody, LYP20, was raised against GMP-140. LYP20, directed against a disulphide bridge-dependent epitope, significantly binds to thrombin-stimulated platelets (12,200 +/- 1,184 bound molecules/platelet, kd = 5.0 +/- 0.61 nmol/L) compared with controls (2,400 +/- 266 molecules/platelet, kd = 2.3 +/- 0.54 nmol/L) and inhibits collagen or thrombin-induced aggregation of washed platelets or platelets in platelet-rich plasma. In addition, LYP20 inhibits rosetting of thrombin-activated platelets to U937 cells. These results strongly suggest that GMP-140 plays an important role in platelet aggregation and platelet interaction with other blood cells. 相似文献
19.
Inhibition of zymosan activation of human neutrophil oxidative metabolism by a mouse monoclonal antibody 总被引:4,自引:0,他引:4
We have studied a neutrophil-specific murine monoclonal antibody, PMN7C3 (IgG3), which specifically alters PMN oxidative metabolism stimulated by serum-opsonized zymosan (STZ) or Candida albicans (STC). Polymorphonuclear cells (PMNs) exposed to PMN7C3 show a significant depression in O2- release (52.8% +/- 2.5% of control), H2O2 release (44.4% +/- 6.0% of control), and O2 consumption (73.9% +/- 2.6% of control) in response to STZ. O2 release in response to phorbol myristate acetate (PMA) was modestly reduced (78.4% +/- 3.7%) by PMN7C3 treatment, but not to the extent seen with STZ or STC. PMN7C3 did not affect O2 release by PMNs stimulated by zymosan opsonized with IgG or by S. aureus, A 23187, or FMLP. PMN7C3 was not cytotoxic, did not trigger oxidative metabolism when used as a stimulus, did not alter STZ- induced degranulation, and did not interfere with binding or uptake of STZ by PMNs. Exposure of PMNs to PMN7C3 decreased PMN rosette formation with erythrocytes coated with C3b (54% of control) or C3bi (63% of control), but had no affect on rosette formation with IgG-coated erythrocytes. PMN7C3 does not bind to monocytes and had no affect on rosette formation by this cell type. Binding of antibody PMN7C3 to the neutrophil surface inhibits the oxidative response to opsonized STZ or STC, possibly in part by altering the function or expression of C3b and C3bi receptors. Monoclonal antibodies such as PMN7C3 provide highly specific probes that may be used to define the molecular features of the stimulus-coupled response of PMN activation. 相似文献
20.
Data are presented to support the concept that the vitamin K-dependent coagulation factors are adsorbed onto the platelet membrane and that these make up part of the "plasma atmosphere" necessary for the aggregation of platelets by various agents. Together with evidence that other coagulation factors also are part of the plasma atmosphere, it is suggested that the aggregation reaction is part of the coagulation sequence. The immunologic approach to demonstrating constituents of the platelet membrane promises to be a highly specific technique for studying further the constituents of the platelet membrane and their reactions in hemostasis. 相似文献